Early identification of immunogenicity risks can make or break a biologic development project. Abzena’s new white paper, Immunogenicity risk assessment in drug candidate selection, explores how integrating in silico and ex vivo testing approaches can help drug developers predict immune responses before they occur.
The paper highlights Abzena’s EpiScreen® 2.0 platform, which uses advanced ex vivo assays to evaluate the immunogenic potential of biologic candidates, and its iTope-AI and TCED™ tools for computational screening. Together, these solutions enable earlier, more accurate risk detection—supporting safer, more efficient biologic development.
Abzena’s integrated approach ensures immunogenicity assessment is not a late-stage consideration but an essential part of the discovery-to-clinic pathway. This proactive strategy helps biopharma companies design safer, more effective molecules and meet evolving regulatory expectations for biologic therapies.
Download the white paper here to read more
